



Review

The Complex Histopathological and Immunohistochemical Spectrum of Neuroendocrine Tumors—An Overview of the Latest Classifications

Ancuța-Augustina Gheorghişan-Gălăţeanu^{1,2}, Andreea Ilieşiu^{3,4}, Ioana Maria Lambrescu^{1,5,*}  and Dana Antonia Țăpoi^{3,4}

¹ Department of Cellular and Molecular Biology and Histology, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania

² C.I. Parhon National Institute of Endocrinology, 011863 Bucharest, Romania

³ Department of Pathology, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania

⁴ Department of Pathology, University Emergency Hospital, 050098 Bucharest, Romania

⁵ Victor Babes National Institute of Pathology, 050096 Bucharest, Romania

* Correspondence: ioana.lambrescu@umfcd.ro

Abstract: Neuroendocrine neoplasms (NENs) originate from the neuroendocrine cell system, which may either take the shape of organoid cell aggregations or be composed of dispersed cells across various organs. Therefore, these tumors are heterogenous regarding the site of origin, functional status, degree of aggressiveness, and prognosis. When treating patients with neuroendocrine tumors, one of the most significant challenges for physicians is determining the correct tumor grade and thus classifying patients into risk categories. Over the years, the classification of these tumors has changed significantly, often causing confusion due to clinical, molecular, and immunohistochemical variability. This review aims to outline the latest NENs classifications regardless of their site of origin. Thus, an overview of the key histopathological and immunohistochemical characteristics of NENs could pave the way to validate possible predictive and prognostic markers and also guide the therapeutic conduct.

Keywords: neuroendocrine tumors; neuroendocrine neoplasms; carcinomas; histopathological classification; tumor grade; Ki67



Citation: Gheorghişan-Gălăţeanu, A.-A.; Ilieşiu, A.; Lambrescu, I.M.; Țăpoi, D.A. The Complex Histopathological and Immunohistochemical Spectrum of Neuroendocrine Tumors—An

Overview of the Latest Classifications. *Int. J. Mol. Sci.* **2023**, *24*, 1418. <https://doi.org/10.3390/ijms24021418>

Academic Editor: Kurt A. Jellinger

Received: 13 December 2022

Revised: 5 January 2023

Accepted: 8 January 2023

Published: 11 January 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Neuroendocrine tumors originate from neuroendocrine cells of the diffuse endocrine system. These cells produce peptide hormones stored in neurosecretory granules and released into the bloodstream [1,2]. Neuroendocrine cells share some common ultrastructural (membrane bound secretory vesicles of varying electron density, abundant rough endoplasmic reticulum and free ribosomes and electron-dense mitochondria) [2,3] and cytochemical characteristics (silver reactivity). Following his discovery of thyroid parafollicular cells, these characteristics prompted A.G.E. Pearse to develop the APUD (Amine Precursor Uptake and Decarboxylation) cell theory and coin the term APUDoma for tumors of APUD cells throughout the body [4,5]. At that time, A.G.E. Pearse assumed that all APUD cells originate from neural crests [4]. However, it is now established that all cells, which share this common structure and function, comprise the diffuse neuroendocrine system. Depending on their embryological origin, these cells may be divided into non-epithelial neuroendocrine cells or epithelial neuroendocrine cells (derived from the neuroectoderm). Epithelial neuroendocrine cells are the most widespread and can be located in both endocrine organs such as the anterior pituitary; the parathyroid (chief cells); and the thyroid (C cells), and diffuse neuroendocrine tissue of the lung, breast, gastrointestinal system, pancreas, genitourinary system, and skin (Merkel cells) [2]. Non-epithelial neuroendocrine cells represent paraganglion cells associated with either sympathetic or

parasympathetic nervous systems in various body parts [6]. Sympathetic paraganglion cells are mainly located in the abdomen, in the connective tissue along the vertebral column, the adrenal medulla, urogenital system, organ of Zuckerkandl [6], gallbladder, and liver [7]. Parasympathetic paraganglion cells are located in the head and neck, in association with cranial nerves and their thoracic branches of the glossopharyngeal and vagus nerve, the carotid body, in the tympanic glia (also known as “glomus jugulare”), the laryngeal paraganglia, the paraganglia of the lungs, and heart [6]. Regardless of their localization and embryological origin, all the neuroendocrine cells can be the source of neuroendocrine tumors, representing an extraordinarily diverse group of neoplasms with variable clinical manifestations, pathological features, and prognosis (Figure 1).




Figure 1. Overview of the epithelial and non-epithelial site of origin for NENs (Created with [Bio.Render.com](https://www.bio-render.com/)).

Due to the heterogeneity of these neoplasms, several different terms have been used to define them. For example, epithelial neuroendocrine neoplasms include tumors described as carcinoid, neuroendocrine tumors, neuroendocrine carcinoma, small-cell carcinoma, thyroid medullary carcinoma, islet cell tumor, Merkel cell carcinoma, argentaffinoma, or APUDoma. In contrast, non-epithelial neuroendocrine neoplasms include paraganglioma, pheochromocytoma, and neuroblastoma [8]. Nevertheless, they all share common immunohistochemical expression of several markers such as chromogranins, synaptophysin, CD56, and Insulinoma-associated protein 1 (INSM1) [8–10]. Therefore, it is now accepted that all tumors displaying predominant neuroendocrine differentiation, regardless of their anatomic site or other histologic features such as tumor grade, should be referred to generally as neuroendocrine neoplasms (NENs) [8]. In addition to this, based on histologic criteria, NENs can be further divided into well-differentiated neoplasms called “neuroendocrine tumors” (NETs) and poorly differentiated neoplasms called “neuroendocrine carcinomas” (NECs) [8,11]. Therefore, the primary objectives of this review are to comprehend the key histopathological characteristics of NENs, with emphasis on the grading system, and to define the most prevalent organ-specific NEN.

2. Histopathological and Immunohistochemical Features in NENs

As previously stated, NENs are classified according to tumor grade into well-differentiated neoplasms (NETs) and poorly differentiated neoplasms (NECs). This dichotomous classification is consistent with significant genetic differences, risk factors, clinical features, and prognosis [8]. NETs often exhibit an “organoid” cell proliferation with sporadic nests, trabecular patterns, and glandular or rosette development [1,11]. Tumor stroma is usually scant with

prominent blood vessels. Occasionally, cell palisading near the periphery of the nests, amyloid stroma, and calcifications with psammoma bodies are seen. The tumor cells are usually epithelioid and closed-packed, but spindle and dis-cohesive cells have also been reported. The cells are medium-sized, with abundant cytoplasm, and uniform round to oval nuclei with inconspicuous nucleoli. The nuclei have characteristic fine to coarsely granular chromatin, giving the classic “salt and pepper” aspect. Mitotic figures are absent or rare [11]. Epithelial NETs express keratins such as AE1/AE3 or CAM5.2. In addition, these cells also display intense immunohistochemical positivity for neuroendocrine markers such as synaptophysin, chromogranin A, somatostatin receptors (SSTRs), or CD56 [11–13].

NECs, on the other hand, present as a solid proliferation of less monomorphic cells with either scant (small-cell types) or abundant (large-cell types) cytoplasm, irregular nuclei with severe nuclear molding, and high mitotic rates [11,12]. Small-cell NECs display hyperchromatic nuclei with “salt and pepper” chromatin, while large-cell NECs exhibit vesicular nuclei with conspicuous nucleolus, which can be large and intensely eosinophilic [11]. Areas of necrosis and apoptotic bodies are commonly reported in NECs [1,11]. In addition, NENs, and especially NECs, can also exhibit a non-neuroendocrine component with various differentiation, such as glandular or squamous [8]. The significant histopathological differences between NETs and NECs are summarized in Table 1.

Table 1. Histopathological differences between NETs and NECs.

Histopathological Features	NETs	NECs
Architecture	“Organoid” proliferation with sporadic nests, trabecular patterns, and glandular or rosette development	Solid proliferation of less monomorphic cells with small-cells or large-cells
Other features	Usually, scant stroma with prominent blood vessels Occasionally, cell palisading at the periphery of the nests, amyloid stroma, calcifications with psammoma bodies	Areas of necrosis, apoptotic bodies
	NENs, especially NECs, can exhibit a non-neuroendocrine component with various differentiation, such as glandular or squamous	
Cell features	Usually epithelioid and closed-packed, rarely spindle and dis-cohesive cells Medium-sized cells with abundant cytoplasm and uniform round to oval nuclei with fine to coarsely granular chromatin and inconspicuous nucleoli (classic “salt and pepper” aspect)	Small-cell: scant cytoplasm, irregular, hyperchromatic nuclei with “salt and pepper” chromatin and severe nuclear molding Large-cell: abundant cytoplasm, vesicular nuclei with conspicuous nucleolus, possibly large and intensely eosinophilic
Mitotic figures	Absent or rare	Frequent

Immunohistochemical positivity for cytokeratins and at least one neuroendocrine marker are required to confirm the diagnosis of NEN. Two distinct neuroendocrine markers are necessary to validate the diagnosis of large-cell NECs [11]. Immunohistochemistry for synaptophysin, SSTRs, and chromogranin A is less useful since their expression is weaker in NECs [11–13]. Most often, NECs remain positive for CD56, but this marker should be interpreted with caution because of its low specificity [13]. As a result, “second-generation” neuroendocrine indicators are now being investigated. INSM1 has emerged as a crucial novel marker for neuroendocrine differentiation, being more sensitive than synaptophysin or chromogranin A and being expressed in both NETs and NECs in many organs. Additionally, its nuclear expression, as opposed to the other neuroendocrine markers with cytoplasmic expression, makes it easier to interpret [10,14–18]. However, INSM1 should not be used as a stand-alone marker for neuroendocrine differentiation, since its expression can be positive in other types of tumors, such as lung squamous cell carcinomas, lung adenocarcinomas, lymphomas, and several different types of sarcomas [19–22]. Another related marker, insulin gene enhancer protein Islet-1 (ISL1), is expressed in var-

ious NENs located in the pancreas, duodenum, colorectum, skin, thyroid, and also in pheochromocytomas/paragangliomas and retains its sensitivity even in neuroendocrine carcinomas [23,24]. The major limitation of ISL1 is its lack of expression in neuroendocrine neoplasms of the small intestine and the appendix [24]. However, combined with other neuroendocrine markers, it may be used to exclude the small intestine as the primary site of a metastatic NEC [25]. The great sensitivity of secretogranin (SECG) expression in NETs and NECs in several organs, including colorectal NENs where chromogranin A is typically negative, has also been documented. Nevertheless, using SECG also has limitations, as this marker is not usually expressed in pheochromocytomas and paragangliomas [23,24]. CD200, a marker for hematopoietic neoplasms, has recently become of interest for neuroendocrine neoplasms. While research is still limited in this field, several authors have demonstrated that CD200 could be a sensitive immunohistochemical marker for neuroendocrine neoplasms of various sites. Additionally, it has been shown that there is a correlation between CD200 expression and tumor grade; as a result, CD200 should be considered a potential therapeutic target [15,26].

3. Histologic Grading of NENs

The classification of NENs according to tumor grade is of the utmost importance since this grading is correlated with the prognosis and therefore influences the therapeutic approach. However, this classification is often the source of great confusion for clinicians, as the defining criteria and terminology of each entity are not universal for every organ and have changed significantly throughout the years [12]. At the beginning of the 20th century, Oberndorfer S. introduced the term “carcinoid”, describing a series of small intestine benign tumors composed of argentaffin-positive and argyrophilic cells [27]. Later in the 20th century, carcinoid tumors were reported in other organs, and some were proven to have aggressive behavior [28,29]. Finally, in 1980, the World Health Organization (WHO) described all NETs, except tumors of endocrine glands and pulmonary neuroendocrine tumors, as carcinoids. This classification caused a lot of controversies, since pathologists referred to all diffuse neuroendocrine tumors as “carcinoids”, although clinicians only associated it with patients displaying symptoms of carcinoid syndrome [12,30]. In 1999, the WHO introduced the terms typical carcinoid, atypical carcinoid, and NEC (either small-cell or large-cell) for pulmonary NETs [12]. However, as the term “carcinoid” remains confusing, the WHO intends to replace it altogether, and its first attempt to do so was the 2000 classification for gastroenteropancreatic NENs. This classification defined the following entities: well-differentiated NETs with presumably benign behavior, well-differentiated NETs with uncertain behavior, and poorly differentiated NECs with high-grade malignant behavior [31]. Since then, the WHO has issued several additional classifications for NENs, although inconsistencies in reporting these lesions have continued due to variances in the criteria for each organ system [8]. Therefore, in 2018, the WHO proposed a standard classification for NENs, regardless of their site of origin [8].

First and foremost, the expert group defined all tumors with predominant neuroendocrine differentiation based on immunohistochemical criteria, whether well or poorly differentiated, as NENs. Furthermore, based on histological criteria, epithelial NENs should be classified as well-differentiated and poorly differentiated. Overall, NETs exhibit non-neoplastic histology to a large extent, while NECs have high-grade histological characteristics. Thus, “neuroendocrine tumor” and “neuroendocrine carcinoma” should be used for well-differentiated NENs and poorly differentiated NENs, respectively. In addition, specific tumor characteristics must be reported for selected organs (e.g., carcinoid tumor, small-cell pulmonary NEC and large-cell pulmonary NEC for lung neuroendocrine neoplasms).

Finally, a grading system was recommended to be implemented for most NENs. According to this system, NETs should generally be graded as G1, G2 and G3, representing low-grade, intermediate-grade and high-grade, respectively. NECs need no further grading, as they are, by definition, high-grade [8]. To grade NENs, three parameters must

be reported: mitotic count, Ki67 labeling index, and the presence or absence of necrosis. However, tumor necrosis is not a grading criterion for gastrointestinal or pancreaticobiliary tumors. The mitotic count should be expressed as mitoses per mm² in up to 10 mm² rather than as mitoses per high-power field (HPF) due to variations in HPF area in microscopes. The Ki67 index must be reported in hotspots of intense labeling of at least 0.4 mm² [8,11]. In 2022, the WHO published its latest Classification of Endocrine and Neuroendocrine Tumors, officially supporting the aforementioned grading system for most NETs; nevertheless, there are still differences in reports for each system. For example, NETs of the gastrointestinal and pancreaticobiliary tract, as well as NETs of the upper aerodigestive tract and salivary glands, are graded using a three-tiered system. However, the grading criteria can differ [8]. In contrast, lung and thymus NETs are classified as typical low-grade carcinoids and intermediate-grade atypical carcinoids corresponding to G1 and G2 grades, respectively. Nevertheless, some authors reported cases of atypical lung carcinoids with high mitotic counts (>10 mitoses/2 mm² and Ki67 > 30%), which could be regarded as an equivalent to NET G3 of the gastrointestinal tract [32,33]. NECs are not subclassified further based on the mitotic activity in any of these organs. Thyroid medullary carcinoma, which is further classified as low-grade or high-grade, is an exception. The major defining criteria for all these entities are presented in Table 2, according to the 2022 WHO Classification of Endocrine and Neuroendocrine Tumors [34].

Table 2. The 2022 World Health Organization Classification of Epithelial Neuroendocrine Neoplasms.

Neuroendocrine Neoplasm	Classification	Defining Criteria
Lung and Thymus		
Well-differentiated neuroendocrine tumor (NET)	Typical carcinoid/NET G1	<2 mitoses/2 mm ² and no necrosis
	Atypical carcinoid/NET G2	2–10 mitoses/2 mm ² and/or necrosis (usually punctate)
	Carcinoid/NET with elevated mitotic counts and/or elevated Ki67 proliferation Index	Atypical carcinoid morphology and elevated mitotic counts (>10 mitoses/2 mm ²) and/or Ki67 > 30%
Poorly differentiated neuroendocrine carcinoma (NEC)	Small-cell lung carcinoma	Small-cell morphology and >10 mitoses/2 mm ²
	Large-cell neuroendocrine lung carcinoma	Large-cell morphology, necrosis always present and >10 mitoses/2 mm ²
Gastrointestinal and pancreatobiliary tract		
Well-differentiated neuroendocrine tumor (NET)	NET, grade 1	<2 mitoses/2 mm ² and/or Ki67 < 3%
	NET, grade 2	2–20 mitoses/2 mm ² and/or Ki67 3–20%
	NET, grade 3	>20 mitoses/2 mm ² and/or Ki67 > 20%
Poorly differentiated neuroendocrine carcinoma (NEC)	Small-cell neuroendocrine carcinoma	Small-cell morphology and >20 mitoses/2 mm ² and/or Ki67 > 20% (often > 70%)
	Large-cell neuroendocrine carcinoma	Large-cell morphology and >20 mitoses/2 mm ² and/or Ki67 > 20% (often > 70%)
Upper aerodigestive tract and salivary glands		
Well-differentiated neuroendocrine tumor (NET)	NET, grade 1	<2 mitoses/2 mm ² , Ki67 < 20% and no necrosis
	NET, grade 2	2–10 mitoses/2 mm ² , Ki67 < 20% and/or necrosis
	NET, grade 3	>10 mitoses/2 mm ² and/or Ki67 > 20%
Poorly differentiated neuroendocrine carcinoma (NEC)	Small-cell neuroendocrine carcinoma	Small-cell morphology and >10 mitoses/2 mm ² and/or Ki67 > 20% (often > 70%)
	Large-cell neuroendocrine carcinoma	Large-cell morphology and >20 mitoses/2 mm ² and/or Ki67 > 20% (often > 55%)

4. Differences between NET G3 and NEC

Recognizing NETs G1 and G2 is usually straightforward, as these tumors display well-differentiated morphological features and low-to-moderate mitotic counts. Distinguishing

between these two entities is based on the proliferative rate. The most problematic situations arise from the difficulty distinguishing NETs G3 from NEC, in which proliferative rates alone do not represent the diagnostic criteria [35]. For example, Ki67 is not a marker that can distinguish between the two, yet NET G3s have lower Ki67 (mean values around 40%) than NEC G3s (mean values > 70%) [36]. Therefore, the definitive diagnosis relies mainly on the morphological features, which can sometimes be challenging to tell apart, particularly on small biopsies. In such cases, NET G3s could be misdiagnosed as NECs due to significant cellular atypia and areas of necrosis [37,38]. To establish the correct diagnosis, in addition to pathology examination, clinical and imaging features should also be considered. For example, patients with NECs present with nonspecific symptoms of an aggressive systemic illness and have undetectable chromogranin levels, rarely exhibiting hormonal symptoms [11,37]. In 2015, Heetfeld and colleagues published a multicentric retrospective study of 204 patients with NETs G3 and NEC. The study's results revealed that patients with NET G3 were more likely to have a functional tumor ($p = 0.003$) than those diagnosed with NEC [39]. In terms of biomarkers such as chromogranin A, urinary 5HIAA, and neuron-specific enolase (NSE), no statistically significant difference was observed between NET G3 and NEC [40].

Epidemiological data are scarce regarding NET G3. However, in contrast to NEC, the primary location for NET G3 is the pancreas, with better overall survival [40,41]. Thus, NET G3 is closer to well-differentiated NET G2 than NEC in terms of prognosis and response rate but with worse overall survival [42].

In imaging studies, NETs can be detected on functional imaging, as they can remain undetected on PET/MRI. Therefore, fluorodeoxyglucose-PET (FDG-PET) is recommended in NEC as part of functional imaging [42]. The clinical and imaging differences can be correlated with some immunohistochemical features of these two entities. NETs are typically positive for specific hormones and strongly express SSTRs [43,44]. In contrast, NECs do not express specific hormones and, except for a few large-cell NECs, are mostly negative or weakly positive for SSTRs [8,43,45]. A positive FDG-PET does not appear to be able to differentiate NEC from NET G3. However, the latter is more likely to have positive somatostatin receptor imaging [40].

Finally, another characteristic that proves the two entities do not overlap is the disparity in response to platinum–etoposide regimens. Thus, Velayoudom-Cephise et al. reported that 31% of large-cell NEC patients had an objective response to platinum–etoposide versus 0% for the NET G3 group [40].

5. Pathological Features of Mixed Neuroendocrine–Non-Neuroendocrine Neoplasms

In addition to pure NENs, pathologists can encounter tumors composed of neuroendocrine and non-neuroendocrine elements. These neoplasms are defined as mixed neuroendocrine–non-neuroendocrine neoplasms (MiNENs) and must distinctively include both components, each with its characteristic morphology and immunohistochemical pattern [11]. These distinctive features must be noted to distinguish MiNENs from other malignancies with scattered neuroendocrine cells or aberrant neuroendocrine expression [11]. Moreover, it is not yet clear what is the exact proportion of each component to make the positive diagnosis of a MiNEN. For gastrointestinal neoplasms, a neuroendocrine component cutoff value of 30% is required for a MiNEN diagnosis. However, the validity of this value is questionable, since it has been proven that a high-grade component has a significant prognostic value even when present in a lower percentage [46]. For other organs, the 2022 WHO Classification of Endocrine and Neuroendocrine Tumors does not list the 30% cutoff criteria for diagnosing MiNENs. Therefore, this value remains in use solely for diagnosing digestive MiNENs, but further studies are needed to determine its predictive value [11]. In light microscopy, the neuroendocrine component of MiNENs is usually represented by NEC, either small or large cells, each exhibiting the characteristic features already mentioned above. Less frequently, the neuroendocrine component can show features of a well-differentiated NET [11]. Along with the distinctive morphology of a MiNEN, the

neuroendocrine component must be confirmed by immunohistochemistry expression of specific neuroendocrine markers. Moreover, the Ki67 proliferation index should also be assessed to grade the neuroendocrine component in cases of mixed tumors [11]. In cases when the neuroendocrine component is a NEC, the Ki67 proliferation index was shown to be a prognostic factor for lung and digestive MiNENs [47,48]. The non-neuroendocrine component is generally represented by the most common subtypes of carcinomas usually found in the affected organ (adenocarcinoma or squamous cell carcinoma) [11].

6. Characteristics of Epithelial NENs Based on the Organ of Origin

6.1. Lung NENs

For lung NENs, additional grading features and the distinction between well-differentiated NETs and poorly differentiated NECs need further clarification. In 2021, the WHO Classification of Thoracic Tumors classified lung NENs as typical carcinoid, atypical carcinoid, and high-grade carcinoma with small or large cells [49]. According to this classification, distinguishing between all these entities relies on cytological features, mitotic count, and whether tumor necrosis is present. The cutoff value of 10 mitoses/2 mm² is the criterion that separates carcinoids from carcinomas [49]. Though not mandatory, the latest WHO classification considers Ki67 a “desirable” feature to be reported, particularly on small biopsies for differentiating carcinoids from carcinomas [49,50]. In this respect, on biopsy samples, Ki67 better predicts the definitive proliferative activity of the resected tumor than the mitotic count [51]. The cutoff value of the Ki67 index used to define each category of lung NENs, and its prognostic value are still up for debate [8]. Some authors recommend Ki67 index assessment in lung NETs [52,53], while others state that it has no particular predictive value [54]. A novel concept of tumors with well-differentiated morphology but high mitotic counts and Ki67 proliferation rates, comparable to G3 NETs of the digestive tract, has evolved as a result of all the recent attempts to establish a classification for lung NENs that may be useful for diagnosis and prognosis [55,56]. However, this category is not officially recognized by the WHO Classification. Therefore, such tumors are classified as NECs [8]. Similar to NECs, these tumors exhibit over 10 mitoses/2 mm² and a Ki67 index > 20% in hotspot areas [55]. Nevertheless, molecular studies suggest that these tumors are related to carcinoids rather than NECs as they present characteristic mutations for carcinoids (MEN1) and lack distinct mutations for NECs (Rb1 and TP53) [32,33,57]. From a clinician’s point of view, it is essential to acknowledge the existence of well-differentiated lung NETs with high proliferation rates because of their distinctive behavior. Although they resemble the clinical course of carcinoids rather than NECs, they tend to be more aggressive and have high recurrence rates [56,58]. Therefore, it is likely that the Ki67 index will become a mandatory feature to be assessed to grade lung NETs, similar to those localized in the digestive tract [32,53].

Small-cell lung carcinomas (SCLCs) are usually easily diagnosed on the standard histopathological exam due to their classic features: small cells with scant cytoplasm with indistinct borders and characteristic nuclei and high mitotic counts of more than 10 mitoses/2 mm². In addition, extensive necrosis and the Azzopardi effect are distinctive [49]. Due to these features, the diagnosis of SCLCs can be frequently established without immunohistochemistry. Nonetheless, immunohistochemical tests may increase diagnostic accuracy [59]. Since around 15–20% of SCLCs are negative for synaptophysin and chromogranin A, additional markers may be used [13]. In addition, most SCLCs express CD56 and/or INSM1 [18,60,61]. In rare cases when all these markers are negative [18] but the diagnosis of SCLC is still morphologically favored, the final diagnosis is established by excluding mimickers with the use of other markers such as CD45 for lymphoma or p40 for the basaloid version of squamous cell carcinoma [13]. In addition, a novel marker, POU2F3, is present in SCLCs that lack expression of existing neuroendocrine markers [62,63].

Large-cell neuroendocrine carcinomas (LCNECs) lack the traditional features of NECs. Instead, they comprise large cells with abundant cytoplasm and vesicular nuclei with prominent nucleoli. However, LCNECs usually display classic neuroendocrine architecture, such as nests with palisading, trabeculae, and rosettes [49]. In this context, the main

differential diagnosis is poorly differentiated non-small-cell lung carcinomas, which makes confirming the neuroendocrine origin using immunohistochemistry mandatory [13].

6.2. Gastrointestinal and Pancreatobiliary NENs

The 2019 WHO Classification of Digestive System Tumors classifies NENs as well-differentiated NETs and poorly differentiated NECs based on morphological criteria [64]. Furthermore, NETs are subclassified based on mitotic count and Ki67 index into low-grade NET G1, intermediate-grade NET G2, and high-grade NET G3. In contrast, NECs are subclassified as either small-cell NEC or large-cell NEC [64]. The ultimate diagnosis for NETs with disparities between the mitotic count and Ki67 index should correspond to the higher grade [1]. According to the WHO classification, cytological characteristics—rather than proliferative activity—are used to distinguish G3 NETs from NECs [64]. Nevertheless, NECs usually show significantly higher proliferation rates than G3 NETs, and the Ki67 assessment can aid in establishing the diagnosis [65,66]. Another difference between these two entities is the expression of SSTRs, which is diffusely positive in NETs but mostly absent in NECs [67]. In addition, immunohistochemistry for p53 and RB1 may be helpful as NECs display either aberrant p53 expression (hyperexpression or null) or null RB1 expression [68]. In contrast, NETs display a wild-type p53 and diffuse RB1 expression [37]. Ultimately, in NETs, chromogranin A expression is diffusely and intensely positive, while in NECs, it is focally and weakly positive [38].

In addition to these general characteristics of gastrointestinal and pancreatobiliary NENs, there are also some site-specific features. For gastric NENs, there are three classic subtypes, as described by Rindi et al. [69], with a fourth subtype observed more recently [70]. Type 1 NENs are the most common. They are associated with chronic atrophic gastritis and hypergastrinemia. The origin of these tumors is represented by enterochromaffin-like (ECL) cells [1,70]. These tumors are generally multifocal, but the prognosis is favorable, with very few cases of metastasis reported [71]. Type 2 NENs occur in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia (MEN). They also originate from ECL cells [70] and are usually G1 or G2 NETs [1], with an overall good prognosis [72]. Type 3 NENs occur sporadically, are not associated with other conditions, and probably originate from ECL cells [70]. This neoplasm is usually solitary and large, with high metastasis rates [1,70,73]. Lastly, type 4 NENs are the rarest, and their cell of origin remains unknown [70]. They are large lesions with aggressive behavior and poor prognosis [74].

NENs have different characteristics throughout the small intestine depending on the affected region. Duodenal NENs can also be classified as well well-differentiated duodenal NETs (Duo-NETs), poorly differentiated neuroendocrine carcinomas (NECs), mixed neuroendocrine–non-neuroendocrine neoplasms (MiNENs), and gangliocytic paragangliomas [75]. Duodenal NETs are mostly G1, but G2 and G3 have also been described [75]. Based on clinical and pathological features, three types of epithelial duodenal NETs have been described: ampullary-type somatostatin-producing NETs (AS-NETs), gastrinomas, and ordinary nonfunctioning NETs [76]. AS-NETs display a tubulo-acinar/pseudoglandular growth pattern, which can cause them to be misdiagnosed as adenocarcinoma. However, AS-NETs are characterized by psammoma bodies' presence, neuroendocrine markers' expression, and SSTRs [75]. The most frequently diagnosed small bowel NENs are represented by well-differentiated serotonin-producing enterochromaffin cell neuroendocrine tumors (EC cell-NETs) located in the distal ileum, followed by gastrin-producing NETs, primarily found in the jejunum. Jejunal-ileal NENs are usually low grade, G3 NETs being rarely reported. NECs are MiNENs are also rarely located in these sites [75].

Appendiceal NETs are the most frequent neoplasms of the appendix, with an incidental diagnosis during appendectomy [77]. They are usually of low or intermediate grade [78] and have an excellent prognosis [64]. Pure NECs are extremely rare and resemble colonic NECs, either the small-cell or large-cell subtype [60]. A more aggressive course characterizes colorectal NENs compared to other digestive NENs [12]. Their prognosis largely depends on tumor stage and grade [63], but rectal NETs, especially G3 (larger

than 1 cm), have a poor prognosis [1,64]. Anal NENs are rare entities [77], usually G1 or G2 [79]. Localized NETs have an excellent prognosis [64,77]. The diagnosis of anal NEC can sometimes be challenging, as it can be misdiagnosed with skin cancers such as basaloid squamous cell carcinoma, basal cell carcinoma, melanoma, or Merkel cell carcinoma [77]. Merkel cell carcinoma, in particular, can be difficult to differentiate as it also expresses neuroendocrine markers. However, Merkel cell carcinoma cells stain positive for CK20 with a distinctive dot-like pattern [80].

Pancreatic NENs are classified into well-differentiated NETs and poorly differentiated NECs. They are all malignant except for the pancreatic neuroendocrine microadenoma, a nonfunctioning NET smaller than 0.5 cm [1,64]. In addition, NETs are divided into functioning and nonfunctioning tumors based on hormone secretion and clinical symptoms. Functioning NETs are most commonly insulinomas, followed by gastrinomas [12]. Other functioning NETs include VIPomas, glucagonomas, and rare types such as somatostatino-mas, ACTH-producing NETs, and serotonin-producing NETs [64,77]. Insulinomas have the best prognosis, but the others are aggressive and often metastasize [1,64]. Another challenge in diagnosing pancreatic NENs is differentiating pancreatic NECs or G3 NETs from an acinar cell carcinoma. In such cases, immunohistochemistry for BCL10 and trypsin is mandatory for the final diagnosis [38,64].

6.3. Head and Neck NENs

The 2016 WHO Classification of Head and Neck Tumors uses different terms for defining NENs depending on their localization. The only recognized entity for the nasal cavity, paranasal sinuses, and skull base is neuroendocrine carcinoma, a poorly differentiated carcinoma with either small- or large-cell morphology [81]. The differential diagnosis of this rare entity includes a variety of other tumors, such as undifferentiated sinonasal carcinoma, NUT carcinoma, mucosal melanoma, embryonal rhabdomyosarcoma, neuroblastoma, or paraganglioma. Thus, a thorough immunohistochemical analysis should be performed to establish the correct diagnosis [8].

For the hypopharynx, larynx, trachea, and parapharyngeal space, the WHO defines the following entities: well-differentiated NEC (also referred to as typical carcinoid or neuroendocrine carcinoma G1), moderately differentiated NEC (also referred to as atypical carcinoid, neuroendocrine carcinoma G2) and poorly differentiated NEC, small or large-cell [81]. The distinction between well-differentiated and moderately differentiated carcinomas is made based on assessing the presence of necrosis and mitotic counts. Necrosis is absent in well-differentiated NEC but present in moderately differentiated cases. The cutoff for mitoses is 2 mitoses/2 mm² [81]. The Ki67 index is not an established criterion for grading these tumors [8].

Chromogranin A and synaptophysin may display weak immunohistochemical expression, particularly in NECs of the head and neck. Therefore, INSM1 may be particularly useful for establishing the diagnosis in such cases [81].

Thyroid NENs are represented by medullary thyroid carcinomas (MTC) [82]. The 2022 WHO Classification of Endocrine Tumors introduced a grading system based on the mitotic count, Ki67 index, and the presence of necrosis. Thus, low-grade MTC display <5 mitoses/2 mm², Ki67 < 5%, and no necrosis. High-grade MTC must display at least one of the following features: ≥5 mitoses/2 mm², Ki67 ≥ 5% or necrosis [83]. In addition to these features, weak immunohistochemical expression of calcitonin may be associated with a less favorable prognosis [8].

6.4. Breast NENs

Breast NENs are rare neoplasms segregated by the WHO Classification of Breast Tumors into NETs G1, NETs G2, and NECs, small and large cells [84]. Breast NETs can be particularly challenging to diagnose since other breast carcinomas can express neuroendocrine markers. Therefore, the distinction between these entities should primarily be based on histological criteria [8,84]. Presently, further grading of NETs as G1 or G2 does

not have well-established criteria, and the Nottingham score can be used according to the WHO classification [84]. In addition, Ki67 rates and necrosis assessment are not clearly defined for evaluating these tumors [8].

6.5. Female Reproductive System NENs

NENs are rare neoplasms of the female genital tract. The most affected site is the cervix, followed by the ovary [12]. According to the 2020 WHO Classification of Female Genital Tumors, they are classified as NETs, G1 or G2, and NECs, small- or large-cell types, in all sites except for the ovary, where the term “carcinoid tumor” is still used [85]. This distinction exists because ovarian NENs are well-differentiated and have an excellent prognosis. NETs can occur in any part of the female genital system. However, in the endometrium and cervix, NECs are much more prevalent than NETs [85]. To establish the diagnosis of NENs in the female reproductive system, immunohistochemical positivity for at least one neuroendocrine marker (chromogranin A, synaptophysin, or CD56) is required. In cases expressing only CD56, the diagnosis of NEN should only be considered in the presence of clear histopathological neuroendocrine features [85].

6.6. Urinary and Male Genital System NENs

Like in most systems, the 2022 WHO Classification of Urinary and Male genital Tumors classifies NENs as NETs, G1 or G2, and NECs, small- or large-cell types [86]. Like other NENs, these tumors express neuroendocrine markers (chromogranin A, synaptophysin, or CD56). Nevertheless, SCNEC lacking chromogranin A or synaptophysin can still be diagnosed based on morphology alone [86]. INSM1 may also be used as it has superior sensitivity to other neuroendocrine markers [86]. The most common lesions in these organs are SCNECs, followed by LCNECs. NETs are extraordinarily rare, and no definitive grading criteria or prognostic factors have been established [87]. In the testis, they may originate from a teratoma or other germ stem tumors [85]. SCNECs often cause a de novo occurrence in the prostate and the bladder [88]. Prostate SCNECs usually represent a transdifferentiation phenomenon in prostate carcinomas treated with anti-androgenic hormones [89]. In such patients, transdifferentiation can also lead to a prostatic LCNEC [87].

6.7. Skin NENs

Skin NENs are high-grade carcinomas, also called Merkel cell carcinomas (MCC). MCC can display small- and large-cell features, but the most common type is the intermediate cell. Consequently, the WHO does not officially subclassify MCC [8,90]. MCCs express neuroendocrine markers (chromogranin A, synaptophysin, or CD56) and display characteristic perinuclear dot-like staining for CK20 and neurofilament (NFT) [90]. Furthermore, the Ki67 index, and necrosis are not used as prognostic factors [8]. Instead, tumor size is the most important prognostic factor, and tumor-infiltrating lymphocytes may also be a prognostic factor [90].

Well-differentiated NENs of the skin are most likely metastatic lesions [8]. However, cases of primary skin well-differentiated NENs have been reported [91] but they should rather be regarded as low-grade sweat gland carcinomas, sebaceous neoplasms, or basal cell carcinomas with neuroendocrine differentiation [8].

The major immunohistochemical features of NENs discussed so far in chapter 6 are summarized in Table 3.

Table 3. Immunohistochemical markers used for diagnosing NENs.

	Chromogranin A, Synaptophysin	Ki67	Other Neuroendocrine Markers	Other Markers for Differential Diagnosis
Lung NENs	Mandatory for LCNECs May be negative in 15–20% of SCLCs	Desirable to be reported, >30% in carcinomas	CD56, INSM1, and/or POU2F3	CD45 for lymphoma or p40 for the basaloid version of squamous cell carcinoma
Gastrointestinal& pancreaticobiliary NENs	Chromogranin A: diffusely and intensely positive in NETs, but focally and weakly positive in NECs	Mandatory for grading NETs	SSTRs: diffusely positive in NETs but mostly absent in NECs	CK20: distinctive dot-like pattern for anal MCCs BCL10 and trypsin: for differentiating pancreatic NECs or G3 NETs from pancreatic acinar cell carcinoma
Head&Neck NENs	May be weakly positive in NECs	No clear cut-off value for NENs of the nasal cavity, paranasal sinuses, skull base, larynx, hypopharynx, trachea, and parapharyngeal space; Mandatory for grading MTC	INSM1: superior sensitivity for NECs; Calcitonin expression: a negative prognostic factor in MTC	For NECs: extensive analysis to exclude undifferentiated sinonasal carcinoma, NUT carcinoma, mucosal melanoma, embryonal rhabdomyosarcoma, neuroblastoma
Breast NENs	Positive but can also be expressed in other type of breast carcinomas	No clear cut-off value		The distinction between breast NENs and other entities should primarily be based on histological criteria
Female Reproductive System NENs	Positive expression of at least one: mandatory for diagnosis	No clear cut-off value	CD56: favors the diagnosis of NENs only in the presence of clear histopathological criteria	
Urinary and Male Genital System NENs	Usually expressed, but not mandatory for diagnosing SCNECs	No clear cut-off value	CD56: low specificity INSM1: superior sensitivity	
Skin NENs	Positive but can also be expressed in other skin carcinomas	No clear cut-off value		CK20 and/or NPF: characteristic dot-like pattern in Merkel Cell Carcinoma

6.8. Pituitary NENs

Adenohypophysial hormone-secreting tumors have historically been referred to as “pituitary adenomas”. Although these tumors can spread locally and even metastatically, no morphologic features predict their aggressiveness [2,8]. In addition, the tumor cells of pituitary adenomas express neuroendocrine markers such as CD56, synaptophysin, chromogranin A, and INSM1. Consequently, the latest WHO Classification of Endocrine and Neuroendocrine Tumors now defines them as pituitary neuroendocrine tumors (PitNETs) and, therefore, are considered malignant [83]. The WHO does not recommend the term “pituitary carcinoma” since no definitive clinical or morphological criteria can accurately predict metastatic potential [2,92]. Therefore, the WHO favors using the term metastatic PitNETs in the presence of spread beyond the point of origin [83].

In the 2022 edition of WHO Classification of Endocrine and Neuroendocrine Tumors, PitNETs are classified based on the immunohistochemical expression of three transcription

factors: (TPIT, PIT1, and SF1), involved in the differentiation of the cell types that give rise to various tumors [83]. Thus, it is recommended to classify PitNETs based on cell lineage according to transcription factors rather than on hormone immunohistochemistry, as this can sometimes be nonspecific [93]. In this respect, diagnosing multiple synchronous PitNETs of different lineages is only possible by analyzing the expression of transcription factors [94]. Therefore, in addition to the transcription factors mentioned above, the definitive classification of PitNETs requires the analysis of other transcription factors (GATA3 and ER-alpha); hormones (GH, PRL, ACTH, beta-TSH, beta-LH, beta-FSH, and alpha-subunit of glycoprotein hormones) and low molecular weight keratins (CAM5.2 and CK8/18) [83,95]. Based on these criteria, the 2022 WHO classification of PitNETs is presented in Table 4.

Table 4. The 2022 WHO classification of PitNETs.

Tumor Type	Transcription Factor(s)	Hormone(s)	Keratin (CAM 5.2 or CK18)
Somatotroph tumors	PIT1	GH, α -subunit	Perinuclear
		GH	Fibrous bodies (>70%)
Lactotroph tumors	PIT1, ER α	PRL (paranuclear)	Weak or negative
		PRL (diffuse cytoplasmic)	Weak or negative
Mammomatotroph tumor	PIT1, ER α	GH (often predominant) PRL, α -subunit	Perinuclear
Thyrotroph tumor	PIT1, GATA2/3	α -subunit, β TSH	Weak or negative
Mature plurihormonal PIT1-lineage tumor	PIT1, ER α , GATA2/3	GH (often predominant), PRL, α -subunit, β TSH	Perinuclear
Acidophil stem cell tumor	PIT1, ER α	PRL (predominant), GH (focal/variable)	Scattered fibrous bodies
Immature PIT1-lineage tumor	PIT1, ER α GATA2/3	GH, PRL, α -subunit, β TSH	Focal/Variable
Corticotroph tumors	TPIT (TBX19), NeuroD1/ β 2	ACTH and other POMC derivatives	Strong
			Variable
Gonadotroph tumor	SF1, ER α GATA2/3	α -subunit, β FSH, β LH	Intense ring-like perinuclear
Unclassified plurihormonal tumors	Multiple combinations	Multiple combinations	Variable
Null cell tumor	None	None	Variable

Ki67 proliferation index is not mandatory, as its predictive value for diagnosing aggressive tumors is still under debate [96]. The prognosis of PitNETs depends on tumor size, type, and local invasion [84,97,98]. Particularly aggressive tumors include immature PIT1 lineage [83], Croke cell [99], “silent” corticotroph [83], sparsely granulated corticotroph [100,101], and null cell tumors [102,103].

7. Non-Epithelial Neuroendocrine Neoplasms

Non-epithelial NENs are derived from neural crests and are called pheochromocytomas when located in the adrenal medulla and paragangliomas when they arise from the extra-adrenal autonomic paraganglia. Pheochromocytomas may also be referred to as intra-adrenal sympathetic paragangliomas. The WHO Classification of Endocrine and Neuroendocrine Tumors, published in 2022, states that non-epithelial NENs are all malignant by definition. However, their prognosis is highly variable and is based on several factors currently under debate [83].

Classic pheochromocytoma/paraganglioma histology is characterized by a nest of cells separated by a network of capillaries (the “zellballen” growth pattern). The tumor cells have abundant granular cytoplasm, which is more basophilic to amphophilic in pheochromocytoma and more eosinophilic in paraganglioma. Nuclear atypia may occur, but mitoses are usually low [8,83]. These tumors also exhibit some distinct immunohistochemical features. Since they are non-epithelial, they do not express keratins but express GATA-3. In addition, sustentacular cells surrounding the nest are S-100- and SOX10-positive [8].

7.1. Pheochromocytomas

Pheochromocytomas (intra-adrenal paragangliomas) may exhibit PAS-positive hyaline globules, lipofuscin inclusions, clear cells, oncocytic or spindle cells, in addition to the previously stated conventional histological characteristics [83]. These histological characteristics may pose diagnostic difficulties, although the immunohistochemistry pattern of positivity for neuroendocrine markers and GATA3 and negative for keratins strongly favors the diagnosis of neuroendocrine tumors rather than the epithelial origin. Additionally, the KI67 labeling index should also be assessed. Its value is usually low in pheochromocytoma (<10%), and higher rates could raise the suspicion of an alternative diagnosis [83].

All pheochromocytomas are considered malignant, with a potential metastasis range from 5% to 15%. Unfortunately, no histological features are formally used to predict the risk of metastasis even though multiple prognosis scores have been developed, such as GAPP (Grading System for Adrenal Pheochromocytoma and Paraganglioma), modified GAPP, PASS (Pheochromocytoma of the Adrenal Gland Scaled Score) [83] and COPPS (Composite Pheochromocytoma/Paraganglioma Prognostic Score) [104]. These scores evaluate histological features such as high cellularity and proliferation rates, comedo necrosis, and capsular or vascular invasion [105].

Another difficulty in managing pheochromocytomas comes from differentiating metastasis from multiple primary paragangliomas. Therefore, metastatic disease can be confirmed only when tumors occur in anatomic sites that cannot be affected by paragangliomas, such as lymph nodes and bones [6]. Even liver and lung involvement must be carefully assessed, since there have been a few isolated reports of primary paragangliomas in those regions [6,7]. Immunohistochemistry can aid the diagnosis as metastasis may lack S100 and SOX10 positive sustentacular cells [83].

7.2. Sympathetic Paragangliomas

Sympathetic paragangliomas affect the prevertebral and paravertebral sympathetic chains, sympathetic nerve plexuses, and sympathetic nerve fibers. They are most often located in the abdomen, retroperitoneum, pelvis, and thorax but can also affect the cervical sympathetic ganglia [83]. These tumors share very similar histological and immunohistochemical features with pheochromocytomas. Therefore, extensive imaging analysis should be used when one needs to differentiate a pheochromocytoma from an extra-adrenal paraganglioma due to a significantly higher risk of metastasis in the case of abdominal paragangliomas [105,106]. Additionally, paragangliomas with unusual locations, especially when they display less typical histological traits, might be confused for other malignancies such as renal cell carcinoma. Therefore, immunohistochemical analysis is mandatory to establish the correct diagnosis [107].

7.3. Parasympathetic Paragangliomas

Parasympathetic paragangliomas usually affect the vagus and glossopharyngeal nerve. Consequently, they are called “head and neck paragangliomas”. However, head and neck tumors can also include sympathetic paragangliomas arising from the cervical sympathetic chain or mixed paragangliomas [83,108].

Parasympathetic paragangliomas are most frequently located around the carotid body, followed by the middle ear and the nodose ganglion [83]. In addition, rare tumors can develop in the sella turcica, orbit, clivus, paranasal sinuses, mandible, parotid gland, nasopharynx, larynx, thyroid, and parathyroids [6,109]. Such rare cases may be misdiagnosed as primary epithelial NENs [83,110]. However, there are rare examples of epithelial NENs that do not express keratins, much as there are paragangliomas that focally express keratins. Nevertheless, immunohistochemical screening for keratins often yields an easy diagnosis [111]. Parasympathetic paragangliomas have a low potential for metastasis [110] but can be locally invasive and have a poor prognosis if surgical resection is not possible [112].

7.4. Composite Pheochromocytoma and Paraganglioma

Composite pheochromocytoma and paraganglioma display features of both pheochromocytoma/paraganglioma and a neurogenic tumor such as ganglioneuroma, ganglioneuroblastoma, neuroblastoma, schwannoma, or malignant peripheral nerve sheath tumors (MPNST) [83,113,114]. To establish the diagnosis of composite pheochromocytoma/paraganglioma, it is necessary to identify at least 5% of each tumor type. Thus, a few isolated neuron-like cells are not sufficient for a final diagnosis [83]. The most common subtype of the non-pheochromocytoma/paraganglioma tumor is ganglioneuroma [79,115]. The prognosis of these tumors depends on the component with the highest grade. The risk of metastasis is significantly higher when the neurogenic component is represented by neuroblastoma or MPNST [83].

8. Conclusions

NENs are a diverse group of tumors that affect almost every organ; exhibit remarkable heterogeneity in terms of morphological traits, clinical presentation, and prognosis; and are widely regarded as malignant. In addition, these tumors are characterized by great heterogeneity in terms of origin, functional status, and aggressiveness. Consequently, in the NENs milieu, the diagnostician’s role in directing treatment has expanded and become more intricate. However, in the past decade, remarkable progress has been made in identifying common features for the entire spectrum of NENs due to advances in cellular and molecular pathology. As a result, it is now accepted that the majority of epithelial NENs can be divided into well-differentiated NETs and poorly differentiated NECs based on well-defined morphological and immunohistochemical criteria. Most NETs can be graded based on mitotic activity, while NECs do not need such a thing, as they always exhibit a high grade. Furthermore, NECs can be divided based on morphological criteria into SCNEC and LCNEC. Nevertheless, some sites, such as the pituitary gland, do not have well-established grading criteria. Still, the latest WHO edition of Endocrine and Neuroendocrine Tumors has considerably improved its classification for PitNETs. As far as non-epithelial NENs are concerned, they should be classified according to the affected site into pheochromocytomas, sympathetic paragangliomas, and parasympathetic paragangliomas, each subgroup with some particular features discussed in this chapter.

Author Contributions: A.-A.G.-G. was involved in the manuscript’s conception, supervision of the study, and critical revision of important intellectual content. A.I. was involved in data collection and microscopic image processing in its final form for publication. I.M.L. was involved in the acquisition and analysis of data and the drafting, and editing of the manuscript. D.A.T. was involved in the study’s design, data collection and manuscript conception. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Kim, J.Y.; Hong, S.-M.; Ro, J.Y. Recent updates on grading and classification of neuroendocrine tumors. *Ann. Diagn. Pathol.* **2017**, *29*, 11–16. [[CrossRef](#)]
2. Asa, S.L.; Mete, O.; Cusimano, M.D.; McCutcheon, I.E.; Perry, A.; Yamada, S.; Nishioka, H.; Casar-Borota, O.; Uccella, S.; La Rosa, S.; et al. Pituitary neuroendocrine tumors: A model for neuroendocrine tumor classification. *Mod. Pathol.* **2021**, *34*, 1634–1650. [[CrossRef](#)] [[PubMed](#)]
3. Ahmed, E.; Abo-Ahmed, A.I.; Latifi, F. Ultrastructure and histochemistry of the subepithelial glands of the nasal septal island in dromedaries with special reference to the possible functions. *Saudi J. Biol. Sci.* **2021**, *28*, 5325–5331. [[CrossRef](#)] [[PubMed](#)]
4. Bussolati, G. C and APUD Cells and Endocrine Tumours. Pearse's Laboratory in the Years 1965–1969: A Personal Recollection. *Endocr. Pathol.* **2014**, *25*, 133–140. [[CrossRef](#)]
5. Pearse, A.G. The APUD cell concept and its implications in pathology. *Pathol. Annu.* **1974**, *9*, 27–41. [[PubMed](#)]
6. Asa, S.L.; Ezzat, S.; Mete, O. The Diagnosis and Clinical Significance of Paragangliomas in Unusual Locations. *J. Clin. Med.* **2018**, *7*, 280. [[CrossRef](#)] [[PubMed](#)]
7. Liao, W.; Ding, Z.Y.; Zhang, B.; Chen, L.; Li, G.X.; Wu, J.J.; Zhang, B.; Chen, X.P.; Zhu, P. Primary functioning hepatic paraganglioma mimicking hepatocellular carcinoma: A case report and literature review. *Medicine* **2018**, *97*, e0293. [[CrossRef](#)]
8. Rindi, G.; Klimstra, D.S.; Abedi-Ardekani, B.; Asa, S.L.; Bosman, F.T.; Brambilla, E.; Busam, K.J.; De Krijger, R.R.; Dietel, M.; El-Naggar, A.K.; et al. A common classification framework for neuroendocrine neoplasms: An International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. *Mod. Pathol.* **2018**, *31*, 1770–1786. [[CrossRef](#)]
9. Klöppel, G. Neuroendocrine Neoplasms: Dichotomy, Origin and Classifications. *Visc. Med.* **2017**, *33*, 324–330. [[CrossRef](#)]
10. Maleki, Z.; Nadella, A.; Nadella, M.; Patel, G.; Patel, S.; Kholová, I. INSM1, a Novel Biomarker for Detection of Neuroendocrine Neoplasms: Cytopathologists' View. *Diagnostics* **2021**, *11*, 2172. [[CrossRef](#)]
11. Rindi, G.; Mete, O.; Uccella, S.; Basturk, O.; La Rosa, S.; Brosens, L.A.A.; Ezzat, S.; de Herder, W.W.; Klimstra, D.S.; Papotti, M.; et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. *Endocr. Pathol.* **2022**, *33*, 115–154. [[CrossRef](#)]
12. Oronsky, B.; Ma, P.C.; Morgensztern, D.; Carter, C.A. Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas. *Neoplasia* **2017**, *19*, 991–1002. [[CrossRef](#)] [[PubMed](#)]
13. Rekhtman, N. Lung neuroendocrine neoplasms: Recent progress and persistent challenges. *Mod. Pathol.* **2021**, *35* (Suppl. S1), 36–50. [[CrossRef](#)]
14. Yuan, C.; Jiao, F.; Zhai, C.; Zhang, J.; Wang, S.; Zhu, L. Application of INSM1 in Diagnosis and Grading of Laryngeal Neuroendocrine Carcinoma. *Laryngoscope* **2021**, *131*, E2662–E2668. [[CrossRef](#)] [[PubMed](#)]
15. Cao, Z.; Cen, H.B.; Wei, J.G.; Qin, L.Z.; Liao, W.; Ao, Q.L. Expression of CD200 and INSM1 in gastrointestinal and pancreatic neuroendocrine neoplasms and its diagnostic values. *Zhonghua Bing Li Xue Za Zhi* **2021**, *50*, 1134–1138. [[PubMed](#)]
16. Seok, J.Y.; Kang, M.; De Peralta-Venturina, M.; Fan, X. Diagnostic Utility of INSM1 in Medullary Thyroid Carcinoma. *Int. J. Surg. Pathol.* **2021**, *29*, 615–626. [[CrossRef](#)]
17. Kawasaki, T.; Kaira, K. Insulinoma-associated protein 1 (INSM1) expression in breast carcinomas with neuroendocrine morphologies: Application and future prospective. *Virchows Arch.* **2021**, *479*, 191–194. [[CrossRef](#)]
18. Sakakibara, R.; Kobayashi, M.; Takahashi, N.; Inamura, K.; Ninomiya, H.; Wakejima, R.; Kitazono, S.; Yanagitani, N.; Horiike, A.; Ichinose, J.; et al. Insulinoma-associated Protein 1 (INSM1) Is a Better Marker for the Diagnosis and Prognosis Estimation of Small Cell Lung Carcinoma Than Neuroendocrine Phenotype Markers Such as Chromogranin A, Synaptophysin, and CD56. *Am. J. Surg. Pathol.* **2020**, *44*, 757–764. [[CrossRef](#)]
19. Wang, M.; Abi-Raad, R.; Baldassarri, R.; Adeniran, A.J.; Cai, G. Expression of insulinoma-associated protein 1 in non-small cell lung cancers: A diagnostic pitfall for neuroendocrine tumors. *Hum. Pathol.* **2021**, *115*, 104–111. [[CrossRef](#)]
20. Tsai, H.K.; Hornick, J.L.; Vivero, M. INSM1 expression in a subset of thoracic malignancies and small round cell tumors: Rare potential pitfalls for small cell carcinoma. *Mod. Pathol.* **2020**, *33*, 1571–1580. [[CrossRef](#)]
21. Warmke, L.M.; Tinkham, E.G.; Ingram, D.R.; Lazar, A.J.; Panse, G.; Wang, W.-L. INSM1 Expression in Angiosarcoma. *Am. J. Clin. Pathol.* **2020**, *155*, 575–580. [[CrossRef](#)]
22. Yoshida, A.; Makise, N.; Wakai, S.; Kawai, A.; Hiraoka, N. INSM1 expression and its diagnostic significance in extraskeletal myxoid chondrosarcoma. *Mod. Pathol.* **2018**, *31*, 744–752. [[CrossRef](#)]
23. Juhlin, C.C. Second-Generation Neuroendocrine Immunohistochemical Markers: Reflections from Clinical Implementation. *Biology* **2021**, *10*, 874. [[CrossRef](#)] [[PubMed](#)]
24. Juhlin, C.C.; Zedenius, J.; Höög, A. Clinical Routine Application of the Second-generation Neuroendocrine Markers ISL1, INSM1, and Secretagoin in Neuroendocrine Neoplasia: Staining Outcomes and Potential Clues for Determining Tumor Origin. *Endocr. Pathol.* **2020**, *31*, 401–410. [[CrossRef](#)] [[PubMed](#)]

25. Selberherr, A.; Koperek, O.; Riss, P.; Scheuba, C.; Kaderli, R.; Perren, A.; Niederle, B. Neuroendocrine Liver Metastasis—a Specific Set of Markers to Detect Primary Tumor Sites. *Endocr. Pathol.* **2019**, *30*, 31–34. [[CrossRef](#)] [[PubMed](#)]
26. Love, J.E.; Thompson, K.; Kilgore, M.R.; Westerhoff, M.; Murphy, C.E.; Papanicolau-Sengos, A.; McCormick, K.A.; Shankaran, V.; Vandeven, N.; Miller, F.; et al. CD200 Expression in Neuroendocrine Neoplasms. *Am. J. Clin. Pathol.* **2017**, *148*, 236–242. [[CrossRef](#)] [[PubMed](#)]
27. Soga, J. The life of S. Oberndorfer: The proposer of the term “carcinoid”—The outcome of a seed in the past 100 years. *Nihon Rinsho. Jpn. J. Clin. Med.* **2009**, *67*, 2201–2206.
28. Williams, E.D.; Sandler, M. The classification of carcinoid tumours. *Lancet* **1963**, *1*, 238–239. [[CrossRef](#)]
29. Arrigoni, M.G.; Woolner, L.B.; Bernatz, P.E. Atypical carcinoid tumors of the lung. *J. Thorac. Cardiovasc. Surg.* **1972**, *64*, 413–421. [[CrossRef](#)]
30. Creutzfeldt, W. Carcinoid Tumors: Development of Our Knowledge. *World J. Surg.* **1996**, *20*, 126–131. [[CrossRef](#)]
31. Klöppel, G. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. *Endocr.-Relat. Cancer* **2011**, *18*, S1–S16. [[CrossRef](#)] [[PubMed](#)]
32. Marchiò, C.; Gatti, G.; Massa, F.; Bertero, L.; Filosso, P.; Pelosi, G.; Cassoni, P.; Volante, M.; Papotti, M. Distinctive pathological and clinical features of lung carcinoids with high proliferation index. *Virchows Arch.* **2017**, *471*, 713–720. [[CrossRef](#)] [[PubMed](#)]
33. Kasajima, A.; Konukiewitz, B.; Oka, N.; Suzuki, H.; Sakurada, A.; Okada, Y.; Kameya, T.; Ishikawa, Y.; Sasano, H.; Weichert, W.; et al. Clinicopathological Profiling of Lung Carcinoids with a Ki67 Index > 20%. *Neuroendocrinology* **2018**, *108*, 109–120. [[CrossRef](#)] [[PubMed](#)]
34. Mete, O.; Asa, S.L.; Gill, A.J.; Kimuta, N.; de Krijger, R.; Tischler, A. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas. *Endocr. Pathol.* **2022**, *33*, 90–114. [[CrossRef](#)] [[PubMed](#)]
35. Tang, L.H.; Untch, B.R.; Reidy, D.L.; O’Reilly, E.; Dhall, D.; Jih, L.; Basturk, O.; Allen, P.J.; Klimstra, D.S. Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas. *Clin. Cancer Res.* **2016**, *22*, 1011–1017. [[CrossRef](#)] [[PubMed](#)]
36. Hofland, J.; Kaltsas, G.; de Herder, W.W. Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms. *Endocr. Rev.* **2020**, *41*, 371–403. [[CrossRef](#)] [[PubMed](#)]
37. Uccella, S.; La Rosa, S.; Metovic, J.; Marchiori, D.; Scoazec, J.Y.; Volante, M.; Mete, O.; Papotti, M. Genomics of High-Grade Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumor with High-Grade Features (G3 NET) and Neuroendocrine Carcinomas (NEC) of Various Anatomic Sites. *Endocr. Pathol.* **2021**, *32*, 192–210. [[CrossRef](#)]
38. La Rosa, S. Challenges in High-grade Neuroendocrine Neoplasms and Mixed Neuroendocrine/Non-neuroendocrine Neoplasms. *Endocr. Pathol.* **2021**, *32*, 245–257. [[CrossRef](#)]
39. Heetfeld, M.; Chougnet, C.N.; Olsen, I.H.; Rinke, A.; Borbath, I.; Crespo, G.; Barriuso, J.; Pavel, M.; O’Toole, D.; Walter, T.; et al. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. *Endocr. Relat. Cancer* **2015**, *22*, 657–664. [[CrossRef](#)] [[PubMed](#)]
40. Velayoudom-Céphise, F.L.; Duvillard, P.; Foucan, L.; Hadoux, J.; Chougnet, C.N.; Leboulleux, S.; Malka, D.; Guigay, J.; Goere, D.; Debaere, T.; et al. Are G3 ENETS neuroendocrine neoplasms heterogeneous? *Endocr. Relat. Cancer* **2013**, *20*, 649–657. [[CrossRef](#)] [[PubMed](#)]
41. Milione, M.; Maisonneuve, P.; Spada, F.; Pellegrinelli, A.; Spaggiari, P.; Albarello, L.; Pisa, E.; Barberis, M.; Vanoli, A.; Buzzoni, R.; et al. The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories. *Neuroendocrinology* **2017**, *104*, 85–93. [[CrossRef](#)]
42. Pellat, A.; Coriat, R. Well Differentiated Grade 3 Neuroendocrine Tumors of the Digestive Tract: A Narrative Review. *J. Clin. Med.* **2020**, *9*, 1677. [[CrossRef](#)] [[PubMed](#)]
43. Dromain, C.; Prior, J.O.; Schaefer, N. Functional and radiological imaging of neuroendocrine neoplasms. In *The Spectrum of Neuroendocrine Neoplasia*; Asa, S.L., La Rosa, S., Mete, O., Eds.; Spindler Nature: Cham, Switzerland, 2021; pp. 29–54.
44. Asa, S.L.; La Rosa, S.; Basturk, O.; Adsay, V.; Minnetti, M.; Grossman, A.B. Molecular Pathology of Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors. *Endocr. Pathol.* **2021**, *32*, 169–191. [[CrossRef](#)] [[PubMed](#)]
45. Duan, K.; Mete, O. Algorithmic approach to neuroendocrine tumors in targeted biopsies: Practical applications of immunohistochemical markers. *Cancer Cytopathol.* **2016**, *124*, 871–884. [[CrossRef](#)]
46. De Mestier, L.; Cros, J.; Neuzillet, C.; Hentic, O.; Egal, A.; Muller, N.; Bouché, O.; Cadiot, G.; Ruszniewski, P.; Couvelard, A.; et al. Digestive System Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms. *Neuroendocrinology* **2017**, *105*, 412–425. [[CrossRef](#)]
47. Milione, M.; Maisonneuve, P.; Pellegrinelli, A.; Grillo, F.; Albarello, L.; Spaggiari, P.; Vanoli, A.; Tagliabue, G.; Pisa, E.; Messerini, L.; et al. Ki67 proliferative index of the neuroendocrine component drives MANEC prognosis. *Endocr.-Relat. Cancer* **2018**, *25*, 583–593. [[CrossRef](#)]
48. Milione, M.; Maisonneuve, P.; Grillo, F.; Mangogna, A.; Centonze, G.; Prinzi, N.; Pusceddu, S.; Garzone, G.; Cattaneo, L.; Busico, A.; et al. Ki-67 Index of 55% Distinguishes Two Groups of Bronchopulmonary Pure and Composite Large Cell Neuroendocrine Carcinomas with Distinct Prognosis. *Neuroendocrinology* **2020**, *111*, 475–489. [[CrossRef](#)]
49. WHO Classification of Tumours Editorial Board. *Thoracic Tumours*, 5th ed.; WHO Classification of Tumours Series; International Agency for Research on Cancer: Lyon, France, 2021; Volume 5.
50. Travis, W.D.B.E.; Burke, A.P.; Marx, A.; Nicholson, A.G. *WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart*, 4th ed.; Bosman, F.T.J.E., Lakhani, S.R., Ohgaki, H., Eds.; International Agency for Research on Cancer: Lyon, France, 2015; p. 412.

51. Moonen, L.; Derks, J.L.; Hermans, B.C.; Bunnik, I.M.; Hillen, L.M.; van Suylen, R.J.; Bakker, M.A.D.; von der Thüsen, J.H.; Damhuis, R.A.; Broek, E.C.V.D.; et al. Preoperative Biopsy Diagnosis in Pulmonary Carcinoids, a Shot in the Dark. *J. Thorac. Oncol.* **2020**, *16*, 610–618. [[CrossRef](#)] [[PubMed](#)]
52. Marchevsky, A.M.; Hendifar, A.; Walts, A.E. The use of Ki-67 labeling index to grade pulmonary well-differentiated neuroendocrine neoplasms: Current best evidence. *Mod. Pathol.* **2018**, *31*, 1523–1531. [[CrossRef](#)]
53. Dermawan, J.K.; Farver, C.F. The Role of Histologic Grading and Ki-67 Index in Predicting Outcomes in Pulmonary Carcinoid Tumors. *Am. J. Surg. Pathol.* **2019**, *44*, 224–231. [[CrossRef](#)]
54. Swarts, D.R.A.; Rudelius, M.; Claessen, S.M.H.; Cleutjens, J.P.; Seidl, S.; Volante, M.; Ramaekers, F.C.S.; Speel, E.J.M. Limited additive value of the Ki-67 proliferative index on patient survival in World Health Organization-classified pulmonary carcinoids. *Histopathology* **2016**, *70*, 412–422. [[CrossRef](#)] [[PubMed](#)]
55. Hermans, B.; Derks, J.; Moonen, L.; Habraken, C.; von der Thüsen, J.; Hillen, L.; Speel, E.; Dingemans, A.-M. Pulmonary neuroendocrine neoplasms with well differentiated morphology and high proliferative activity: Illustrated by a case series and review of the literature. *Lung Cancer* **2020**, *150*, 152–158. [[CrossRef](#)] [[PubMed](#)]
56. Quinn, A.M.; Chaturvedi, A.; Nonaka, D. High-grade Neuroendocrine Carcinoma of the Lung with Carcinoid Morphology: A Study of 12 Cases. *Am. J. Surg. Pathol.* **2017**, *41*, 263–270. [[CrossRef](#)]
57. Rekhtman, N.; Desmeules, P.; Litvak, A.M.; Pietanza, M.C.; Santos-Zabala, M.L.; Ni, A.; Montecalvo, J.; Chang, J.C.; Beras, A.; Preeshagul, I.R.; et al. Stage IV lung carcinoids: Spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices. *Mod. Pathol.* **2019**, *32*, 1106–1122. [[CrossRef](#)] [[PubMed](#)]
58. Clay, V.; Papaxoinis, G.; Sanderson, B.; Valle, J.W.; Howell, M.; Lamarca, A.; Krysiak, P.; Bishop, P.; Nonaka, D.; Mansoor, W. Evaluation of diagnostic and prognostic significance of Ki-67 index in pulmonary carcinoid tumours. *Clin. Transl. Oncol.* **2016**, *19*, 579–586. [[CrossRef](#)] [[PubMed](#)]
59. Thunnissen, E.; Borczuk, A.C.; Flieder, D.B.; Witte, B.; Beasley, M.B.; Chung, J.H.; Dacic, S.; Lantuejoul, S.; Russell, P.A.; den Bakker, M.; et al. The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases. *J. Thorac. Oncol.* **2017**, *12*, 334–346. [[CrossRef](#)]
60. Rooper, L.; Sharma, R.; Li, Q.K.; Illei, P.B.; Westra, W.H. INSM1 Demonstrates Superior Performance to the Individual and Combined Use of Synaptophysin, Chromogranin and CD56 for Diagnosing Neuroendocrine Tumors of the Thoracic Cavity. *Am. J. Surg. Pathol.* **2017**, *41*, 1561–1569. [[CrossRef](#)]
61. Mukhopadhyay, S.; Dermawan, J.K.; Lanigan, C.P.; Farver, C.F. Insulinoma-associated protein 1 (INSM1) is a sensitive and highly specific marker of neuroendocrine differentiation in primary lung neoplasms: An immunohistochemical study of 345 cases, including 292 whole-tissue sections. *Mod. Pathol.* **2018**, *32*, 100–109. [[CrossRef](#)]
62. Baine, M.K.; Hsieh, M.-S.; Lai, W.V.; Egger, J.V.; Jungbluth, A.A.; Daneshbod, Y.; Beras, A.; Spencer, R.; Lopardo, J.; Bodd, F.; et al. SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization. *J. Thorac. Oncol.* **2020**, *15*, 1823–1835. [[CrossRef](#)]
63. Huang, Y.-H.; Klingbeil, O.; He, X.; Wu, X.S.; Arun, G.; Lu, B.; Somerville, T.D.; Milazzo, J.P.; Wilkinson, J.E.; Demerdash, O.E.; et al. POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer. *Genes Dev.* **2018**, *32*, 915–928. [[CrossRef](#)]
64. Nagtegaal, I.D.; Odze, R.D.; Klimstra, D.; Paradis, V.; Rugge, M.; Schirmacher, P.; Washington, K.M.; Carneiro, F.; Cree, I.A. WHO Classification of Tumours Editorial Board The 2019 WHO Classification of Tumours of the Digestive System. *Histopathology* **2020**, *76*, 182–188. [[CrossRef](#)] [[PubMed](#)]
65. Kim, H.; An, S.; Lee, K.; Ahn, S.; Park, D.Y.; Kim, J.H.; Kang, D.W.; Kim, M.J.; Chang, M.S.; Jung, E.S.; et al. Gastrointestinal Pathology Study Group of the Korean Society of Pathologists. Pancreatic High-Grade Neuroendocrine Neoplasms in the Korean Population: A Multi-center Study. *Cancer Res. Treat.* **2020**, *52*, 263–276. [[CrossRef](#)] [[PubMed](#)]
66. Raj, N.; Valentino, E.; Capanu, M.; Tang, L.H.; Basturk, O.; Untch, B.R.; Allen, P.J.; Klimstra, D.S.; Reidy-Lagunes, D. Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated. *Pancreas* **2017**, *46*, 296–301. [[CrossRef](#)]
67. Inzani, F.; Rindi, G. Introduction to neuroendocrine neoplasms of the digestive system: Definition and classification. *Pathologica* **2021**, *113*, 1–4. [[CrossRef](#)]
68. Fang, J.M.; Li, J.; Shi, J. An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms. *World J. Gastroenterol.* **2022**, *28*, 1009–1023. [[CrossRef](#)] [[PubMed](#)]
69. Rindi, G.; Luinetti, O.; Cornaggia, M.; Capella, C.; Solcia, E. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: A clinicopathologic study. *Gastroenterology* **1993**, *104*, 994–1006. [[CrossRef](#)]
70. Köseoğlu, H.; Duzenli, T.; Sezikli, M. Gastric neuroendocrine neoplasms: A review. *World J. Clin. Cases* **2021**, *9*, 7973–7985. [[CrossRef](#)]
71. Tsolakis, A.V.; Ragkousi, A.; Vujasinovic, M.; Kaltsas, G.; Daskalakis, K. Gastric neuroendocrine neoplasms type 1: A systematic review and meta-analysis. *World J. Gastroenterol.* **2019**, *25*, 5376–5387. [[CrossRef](#)]
72. Delle Fave, G.; O’Toole, D.; Sundin, A.; Taal, B.; Ferolla, P.; Ramage, J.; Ferone, D.; Ito, T.; Weber, W.; Zheng-Pei, Z.; et al. ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. *Neuroendocrinology* **2016**, *103*, 119–124. [[CrossRef](#)]
73. Panzuto, F.; Campana, D.; Massironi, S.; Faggiano, A.; Rinzivillo, M.; Lamberti, G.; Sciola, V.; Lahner, E.; Manuzzi, L.; Colao, A.; et al. Tumour type and size are prognostic factors in gastric neuroendocrine neoplasia: A multicentre retrospective study. *Dig. Liver Dis.* **2019**, *51*, 1456–1460. [[CrossRef](#)]

74. Ahmed, M. Gastrointestinal neuroendocrine tumors in 2020. *World J. Gastrointest. Oncol.* **2020**, *12*, 791–807. [[CrossRef](#)] [[PubMed](#)]
75. Milione, M.; Parente, P.; Grillo, F.; Zamboni, G.; Mastracci, L.; Capella, C.; Fassan, M.; Vanoli, A. Neuroendocrine neoplasms of the duodenum, ampullary region, jejunum and ileum. *Pathologica* **2021**, *113*, 12–18. [[CrossRef](#)]
76. Vanoli, A.; La Rosa, S.; Klersy, C.; Grillo, F.; Albarello, L.; Inzani, F.; Maragliano, R.; Manca, R.; Luinetti, O.; Milione, M.; et al. Four Neuroendocrine Tumor Types and Neuroendocrine Carcinoma of the Duodenum: Analysis of 203 Cases. *Neuroendocrinology* **2016**, *104*, 112–125. [[CrossRef](#)]
77. Assarzadegan, N.; Montgomery, E. What is New in the 2019 World Health Organization (WHO) Classification of Tumors of the Digestive System: Review of Selected Updates on Neuroendocrine Neoplasms, Appendiceal Tumors, and Molecular Testing. *Arch. Pathol. Lab. Med.* **2020**, *145*, 664–677. [[CrossRef](#)] [[PubMed](#)]
78. Hrabec, J. Neuroendocrine Tumors of the Appendix, Colon, and Rectum. *Surg. Oncol. Clin. N. Am.* **2020**, *29*, 267–279. [[CrossRef](#)]
79. Gut, P.; Waligórska-Stachura, J.; Czarnywojtek, A.; Sawicka-Gutaj, N.; Bączyk, M.; Ziemnicka, K.; Woliński, K.; Zybek, A.; Fischbach, J.; Ruchała, M. Hindgut neuroendocrine neoplasms—Characteristics and prognosis. *Arch. Med. Sci.* **2017**, *13*, 1427–1432. [[CrossRef](#)]
80. Pasternak, S.; Carter, M.D.; Ly, T.Y.; Doucette, S.; Walsh, N.M. Immunohistochemical profiles of different subsets of Merkel cell carcinoma. *Hum. Pathol.* **2018**, *82*, 232–238. [[CrossRef](#)] [[PubMed](#)]
81. WHO Classification of Tumours Editorial Board. *Head and Neck Tumours*, 5th ed.; WHO Classification of Tumours Series; International Agency for Research on Cancer: Lyon, France, 2022; Volume 9.
82. Asa, S.L.; Mete, O. Endocrine pathology: Past, present and future. *Pathology* **2017**, *50*, 111–118. [[CrossRef](#)]
83. WHO Classification of Tumours Editorial Board. *Endocrine and Neuroendocrine Tumours*, 5th ed.; WHO Classification of Tumours Series; International Agency for Research on Cancer: Lyon, France, 2022; Volume 10.
84. WHO Classification of Tumours Editorial Board. *Breast Tumours*, 5th ed.; WHO Classification of Tumours Series; International Agency for Research on Cancer: Lyon, France, 2019; Volume 2.
85. WHO Classification of Tumours Editorial Board. *Female Genital Tumours*, 5th ed.; WHO Classification of Tumours Series; International Agency for Research on Cancer: Lyon, France, 2020; Volume 4.
86. WHO Classification of Tumours Editorial Board. *Urinary and Male Genital Tumours*, 5th ed.; WHO Classification of Tumours Series; International Agency for Research on Cancer: Lyon, France, 2022; Volume 8.
87. Shehabeldin, A.N.; Ro, J.Y. Neuroendocrine tumors of genitourinary tract: Recent advances. *Ann. Diagn. Pathol.* **2019**, *42*, 48–58. [[CrossRef](#)]
88. Zaffuto, E.; Pompe, R.S.; Zanaty, M.; Bondarenko, H.D.; Leyh-Bannurah, S.-R.; Moschini, M.; Dell’Oglio, P.; Gandaglia, G.; Fossati, N.; Stabile, A.; et al. Contemporary Incidence and Cancer Control Outcomes of Primary Neuroendocrine Prostate Cancer: A SEER Database Analysis. *Clin. Genitourin. Cancer* **2017**, *15*, e793–e800. [[CrossRef](#)]
89. Akamatsu, S.; Inoue, T.; Ogawa, O.; Gleave, M.E. Clinical and molecular features of treatment-related neuroendocrine prostate cancer. *Int. J. Urol.* **2018**, *25*, 345–351. [[CrossRef](#)] [[PubMed](#)]
90. WHO Classification of Tumours Editorial Board. *Skin Tumours*, 4th ed.; WHO Classification of Tumours Series; International Agency for Research on Cancer: Lyon, France, 2018.
91. Goto, K.; Anan, T.; Nakatsuka, T.; Kaku, Y.; Sakurai, T.; Fukumoto, T.; Kimura, T.; Shibata, A. Low-Grade Neuroendocrine Carcinoma of the Skin (Primary Cutaneous Carcinoid Tumor) as a Distinctive Entity of Cutaneous Neuroendocrine Tumors: A Clinicopathologic Study of 3 Cases With Literature Review. *Am. J. Dermatopathol.* **2017**, *39*, 250–258. [[CrossRef](#)] [[PubMed](#)]
92. Asa, S.L.; Mete, O.; Ezzat, S. Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know? *Endocr. Pathol.* **2021**, *32*, 3–16. [[CrossRef](#)] [[PubMed](#)]
93. Mete, O.; Asa, S.L. Structure, Function, and Morphology in the Classification of Pituitary Neuroendocrine Tumors: The Importance of Routine Analysis of Pituitary Transcription Factors. *Endocr. Pathol.* **2020**, *31*, 330–336. [[CrossRef](#)]
94. Mete, O.; Alshaiikh, O.M.; Cintosun, A.; Ezzat, S.; Asa, S.L. Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages. *Endocr. Pathol.* **2018**, *29*, 332–338. [[CrossRef](#)]
95. Asa, S.L.; Mete, O. Cytokeratin profiles in pituitary neuroendocrine tumors. *Hum. Pathol.* **2020**, *107*, 87–95. [[CrossRef](#)]
96. Grimm, F.; Maurus, R.; Beschorner, R.; Naros, G.; Stanojevic, M.; Gugel, I.; Giese, S.; Bier, G.; Bender, B.; Honegger, J. Ki-67 labeling index and expression of p53 are non-predictive for invasiveness and tumor size in functional and nonfunctional pituitary adenomas. *Acta Neurochir.* **2019**, *161*, 1149–1156. [[CrossRef](#)]
97. Asioli, S.; Righi, A.; Iommi, M.; Baldovini, C.; Ambrosi, F.; Guaraldi, F.; Zoli, M.; Mazzatenta, D.; Faustini-Fustini, M.; Rucci, P.; et al. Validation of a clinicopathological score for the prediction of post-surgical evolution of pituitary adenoma: Retrospective analysis on 566 patients from a tertiary care centre. *Eur. J. Endocrinol.* **2019**, *180*, 127–134. [[CrossRef](#)]
98. Lenders, N.F.; Wilkinson, A.C.; Wong, S.J.; Shein, T.T.; Harvey, R.J.; Inder, W.J.; Earls, P.E.; McCormack, A.I. Transcription factor immunohistochemistry in the diagnosis of pituitary tumours. *Eur. J. Endocrinol.* **2021**, *184*, 891–901. [[CrossRef](#)]
99. Cortez, G.M.; Monteiro, A.; Agnoletto, G.; Bit-Ivan, E.N.; Sauvageau, E.; Hanel, R.A. Aggressive Pituitary Tumor with Crouse’s Cells and Invasion of the Posterior Fossa. *World Neurosurg.* **2020**, *138*, 530–534.e1. [[CrossRef](#)]
100. Dogansen, S.C.; Bilgic, B.; Yalin, G.Y.; Tanrikulu, S.; Yarman, S. Clinical significance of granulation pattern in corticotroph pituitary adenomas. *Turk. J. Pathol.* **2018**, *35*, 9–14. [[CrossRef](#)]

101. Rak, B.; Maksymowicz, M.; Pękuł, M.; Zieliński, G. Clinical, Biological, Radiological Pathological and Immediate Post-Operative Remission of Sparsely and Densely Granulated Corticotroph Pituitary Tumors: A Retrospective Study of a Cohort of 277 Patients with Cushing's Disease. *Front. Endocrinol.* **2021**, *12*, 672178. [[CrossRef](#)]
102. Almeida, J.P.; Stephens, C.C.; Eschbacher, J.M.; Felicella, M.M.; Yuen, K.C.J.; White, W.L.; Mooney, M.A.; Bernat, A.L.; Mete, O.; Zadeh, G.; et al. Clinical, pathologic, and imaging characteristics of pituitary null cell adenomas as defined according to the 2017 World Health Organization criteria: A case series from two pituitary centers. *Pituitary* **2019**, *22*, 514–519. [[CrossRef](#)] [[PubMed](#)]
103. Haddad, A.F.; Young, J.S.; Oh, T.; Pereira, M.P.; Joshi, R.S.; Pereira, K.M.; Osorio, R.C.; Donohue, K.C.; Peeran, Z.; Sudhir, S.; et al. Clinical characteristics and outcomes of null-cell versus silent gonadotroph adenomas in a series of 1166 pituitary adenomas from a single institution. *Neurosurg. Focus* **2020**, *48*, E13. [[CrossRef](#)]
104. Pierre, C.; Agopianz, M.; Brunaud, L.; Battaglia-Hsu, S.-F.; Max, A.; Pouget, C.; Nomine, C.; Lomazzi, S.; Vignaud, J.-M.; Weryha, G.; et al. COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas. *Virchows Arch.* **2019**, *474*, 721–734. [[CrossRef](#)]
105. Thompson, L.D.R.; Gill, A.J.; Asa, S.L.; Clifton-Bligh, R.J.; de Krijger, R.R.; Kimura, N.; Komminoth, P.; Lack, E.E.; Lenders, J.W.M.; Lloyd, R.V.; et al. Data set for the reporting of pheochromocytoma and paraganglioma: Explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting. *Hum. Pathol.* **2021**, *110*, 83–97. [[CrossRef](#)]
106. Crona, J.; Lamarca, A.; Ghosal, S.; Welin, S.; Skogseid, B.; Pacak, K. Genotype–phenotype correlations in pheochromocytoma and paraganglioma: A systematic review and individual patient meta-analysis. *Endocr.-Relat. Cancer* **2019**, *26*, 539–550. [[CrossRef](#)]
107. Hempenstall, L.E.; Siriwardana, A.R.; Desai, D.J. Investigation of a renal mass: Diagnosing renal paraganglioma. *Urol. Case Rep.* **2018**, *21*, 8–9. [[CrossRef](#)]
108. Dandpat, S.K.; Rai, S.K.R.; Shah, A.; Goel, N.; Goel, A.H. Silent stellate ganglion paraganglioma masquerading as schwannoma: A surgical nightmare. *J. Craniovertebr. Junction Spine* **2020**, *11*, 240–242. [[PubMed](#)]
109. Ruzevick, J.; Koh, E.K.; Gonzalez-Cuyar, L.F.; Cimino, P.J.; Moe, K.; Wright, L.A.; Failor, R.; Ferreira, M. Clival paragangliomas: A report of two cases involving the midline skull base and review of the literature. *J. Neuro-Oncol.* **2017**, *132*, 473–478. [[CrossRef](#)] [[PubMed](#)]
110. Williams, M.D. Paragangliomas of the Head and Neck: An Overview from Diagnosis to Genetics. *Head Neck Pathol.* **2017**, *11*, 278–287. [[CrossRef](#)] [[PubMed](#)]
111. Dermawan, J.K.; Mukhopadhyay, S.; Shah, A.A. Frequency and extent of cytokeratin expression in paraganglioma: An immunohistochemical study of 60 cases from 5 anatomic sites and review of the literature. *Hum. Pathol.* **2019**, *93*, 16–22. [[CrossRef](#)] [[PubMed](#)]
112. Zhou, Y.Y.; Coffey, M.; Mansur, D.; Wasman, J.; Asa, S.L.; Couce, M. Images in Endocrine Pathology: Progressive Loss of Sustentacular Cells in a Case of Recurrent Jugulotympanic Paraganglioma over a Span of 5 years. *Endocr. Pathol.* **2020**, *31*, 310–314. [[CrossRef](#)]
113. Chatterjee, U.; Mukherjee, S.; Mondal, A.; Sengupta, M.; Sarkar, D.; Mukhopadhyay, S. Composite phaeochromocytoma with malignant peripheral nerve sheath tumour: A case report with summary of prior published cases. *Indian J. Pathol. Microbiol.* **2021**, *64*, 571. [[CrossRef](#)]
114. Dhanasekar, K.; Visakan, V.; Tahir, F.; Balasubramanian, S.P. Composite phaeochromocytomas—A systematic review of published literature. *Langenbeck's Arch. Surg.* **2021**, *407*, 517–527. [[CrossRef](#)]
115. Chen, J.; Wu, Y.; Wang, P.; Wu, H.; Tong, A.; Chang, X. Composite pheochromocytoma/paraganglioma-ganglioneuroma: Analysis of SDH and ATRX status, and identification of frequent HRAS and BRAF mutations. *Endocr. Connect.* **2021**, *10*, 926–934. [[CrossRef](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.